Veeva Enables CROs to Build Studies Faster with Vault EDC
19.5.2020 10:00:00 EEST | Business Wire | Press release
2020 Veeva R&D Summit, Europe — Veeva Systems (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC. As part of the CRO partner program, CROs are trained and receive best practices configuring casebooks directly from a protocol with Studio, a new design innovation in Vault EDC to reduce study build times. Ten global CROs, including 5 of the top 7 largest CROs, are already part of the program to configure studies for sponsors.
Vault EDC enables an agile design approach for configuring casebooks by making it easier for clinical programmers to reuse forms, components, and rules during the database build. CROs can collaborate more effectively with sponsors during the build process and make changes to the case report form in real-time. This significantly reduces the time and effort of clinical programmers to build a study database so that data collection can start sooner.
With the CRO partner program, Veeva is enabling a growing network of CROs trained to configure casebooks in Vault EDC. CROs receive 2-4 weeks of training, best practices in agile design, and mentoring during their first casebook build. CROs are fully trained to build complex studies and make mid-study changes quickly with Vault EDC.
“We are making it easier for CROs to build quality studies and get them up and running faster for sponsors,” said Richard Young, vice president of strategy for Veeva Vault CDMS. “Sponsors can have the confidence that CROs are ready to configure the most complex studies and deploy study amendments faster than ever before with Veeva Vault EDC.”
In other news, Veeva today announced MyVeeva, a multichannel patient portal for virtual visits and patient-centric trials, and Veeva Vault Site Connect, an application that connects sponsors and clinical research sites during studies. Both are part of the Veeva Clinical Network, a set of solutions that enables sponsors, sites, and patients to share and view information and accelerate clinical research.
Learn more about Vault EDC and Vault CDMS at the online Veeva R&D Summit, 19-20 and 26 May, 2020. CROs interested in hearing more about the partner program can contact info@veeva.com.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005183/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 15:17:00 EEST | Press release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 15:17:00 EEST | Press release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Saildrone Unveils Spectre, a New Class of High-Speed Unmanned Surface Vessel for Naval Operations20.4.2026 15:00:00 EEST | Press release
Saildrone, the world leader and most experienced operator of unmanned surface vehicles (USVs), today released the design of the Saildrone Spectre, the culmination of two years of intense design work, leveraging over 10 years of operational USV experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420620393/en/ Two Saildrone Spectre variants are built around different mission needs: Spectre Silent Endurance (right) uses wing assist for extreme endurance and silent propulsion. Spectre Stealth Strike (left) meets all mUSV requirements. At 52 meters (170 feet) long, weighing 250 tonnes, and capable of up to 30 knots, Spectre is the largest, fastest, and most capable Saildrone platform to date. Spectre is optimized for anti-submarine warfare (ASW) operations, a mission set that demands extreme endurance and an ultra-quiet acoustic signature. Spectre achieves this by leveraging the proven endurance, reliability, and silent
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom